These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 8290968

  • 1. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R, Ho AD, Del Valle F, Fischer JT, Ehrhardt R, Döhner H, Witt B, Huberts H, Kaplan E, Hunstein W.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [Abstract] [Full Text] [Related]

  • 2. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 3. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R, Lerede T, Buelli M, Borleri G, Bellavita P, Rambaldi A, Barbui T.
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [Abstract] [Full Text] [Related]

  • 4. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [Abstract] [Full Text] [Related]

  • 5. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Dec; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 6. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD, Del Valle F, Haas R, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Thiel E, Andreesen R, Fiedler W.
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [Abstract] [Full Text] [Related]

  • 7. Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
    Van Der Jagt R, Robinson KS, Belch A, Yetisir E, Wells G, Larratt L, Shustik C, Gluck S, Stewart K, Sheridan D, Canadian Leukemia Studies Group.
    Leuk Lymphoma; 2006 Apr; 47(4):697-706. PubMed ID: 16690529
    [Abstract] [Full Text] [Related]

  • 8. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F, Fernández-Barbieri MA, Santarelli MT, Matus-Ridley M, Rosso A, Negri-Aranguren P, Cerutti I, Gomel M, Kvicala R.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [Abstract] [Full Text] [Related]

  • 9. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 10. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
    He XY, Pohlman B, Lichtin A, Rybicki L, Kalaycio M.
    Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
    [Abstract] [Full Text] [Related]

  • 11. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
    Pierri I, Clavio M, Beltrami G, Cavaliere M, Lanza L, Miglino M, Canepa L, Pietrasanta D, Ballerini F, Quintino S, Gatto S, Celesti L, Carrara P, Varese P, Gobbi M.
    J Exp Clin Cancer Res; 1999 Mar; 18(1):55-60. PubMed ID: 10374678
    [Abstract] [Full Text] [Related]

  • 12. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P, Vítek A, Michalová K, Zemanová Z, Lukásová M.
    Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
    [Abstract] [Full Text] [Related]

  • 13. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 14. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
    Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM.
    Cancer; 1999 Jan 15; 85(2):358-67. PubMed ID: 10023703
    [Abstract] [Full Text] [Related]

  • 15. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
    Visani G, Lemoli R, Tosi P, Martinelli G, Testoni N, Ricci P, Motta M, Gherlinzoni F, Leopardi G, Pastano R, Rizzi S, Piccaluga P, Isidori A, Tura S.
    Bone Marrow Transplant; 1999 Sep 15; 24(5):467-72. PubMed ID: 10482929
    [Abstract] [Full Text] [Related]

  • 16. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
    Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Knöbl P, Jäger U, Lechner K, Valent P.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):3965-71. PubMed ID: 15217926
    [Abstract] [Full Text] [Related]

  • 17. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M.
    Br J Haematol; 2005 Oct 15; 131(2):172-9. PubMed ID: 16197446
    [Abstract] [Full Text] [Related]

  • 18. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 19. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V.
    Ann Hematol; 2003 Apr 15; 82(4):231-5. PubMed ID: 12707726
    [Abstract] [Full Text] [Related]

  • 20. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb 15; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.